A Phase II Trial to Assess Hemodynamic Effects of Istaroxime in Pts With Worsening HF and Reduced LV Systolic Function - Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00616161

Sponsors and Collaborators

sigma-tau i.f.r. S.p.A.

MDS Pharma Services

Investigators


Study Chair:	Mihai Gheorghiade, MD FACC	Northwestern University Feinberg School of Medicine - Chicago

Principal Investigator:	Witold Ruzyllo, MD	National Institute of Cardiology, Department of Coronary Artery Disease - Warsaw - POLAND

Principal Investigator:	Cezar Macarie, MD	Insitutul de Boli Cardiovasculare C.C. Iliescu Bucuresti, Bucharest - ROMANIA

Principal Investigator:	Dimitrios Th Kremastinos, MD	Second Cardiology Department, Athens University Medical School, University Hospital Attikon, Athens - GREECE

Principal Investigator:	Serban I Bubenek-Turconi, MD	First Anaesth. & Intensive Care Dept., CC Iliescu Heart Disease Institute, Bucharest - ROMANIA

Principal Investigator:	Maria Dorobantu, MD	Emergency Hospital "Loreasca", Bucharest - ROMANIA

Principal Investigator:	Jerzy Korewicki, MD	Institute of Cardiology, Warsaw, Poland

Principal Investigator:	Jaroslaw Drodz, MD	Hospital bieganskieko , Dept of Cardiology, Lodz - POLAND

Principal Investigator:	Piotr Ponikowski, MD	Iv Military Hospital, Wroclaw, POLAND

Principal Investigator:	John N Nanas, MD PhD	Alexandra University Hospital, Athens - GREECE